AbCellera Biologics Inc. (ABCL) Stock Ticker
ABCL right now
Market factors today
Unlock the full ABCL picture
About AbCellera Biologics Inc.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
ABCL stock facts
| Ticker symbol | ABCL |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $3.9B |
| CEO | Carl Hansen |
| Employees | 562 |
| Headquarters | Vancouver, BC, CA |
| IPO date | 2020-12-11 |
| Website | www.abcellera.com |
What you can see for ABCL on Tickr
Live ABCL price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ABCL report.
Rankings
ABCL peers
FAQ
What is the ticker symbol for AbCellera Biologics Inc.?
The ticker symbol for AbCellera Biologics Inc. is ABCL, listed on the NASDAQ Global Select.
What is ABCL?
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or…